Medigen’s MVC-COV1901 Selected for WHO COVID-19 Solidarity Trial Vaccines
|
By IntellAsia: Resources
on 10/26/2021
TAIPEI, Oct. 27, 2021 /PRNewswire/ -- Medigen Vaccine Biologics Corp (MVC) vaccine candidate, MVC-COV1901, has been recommended by an independent vaccine prioritisation advisory group to be included in the World H...
Full "IntellAsia: Resources" article
|
|